JEFFREY MILBRANDT, M.D.
Medical Practice at Euclid Ave, Saint Louis, MO
License number
Missouri R2E28
Category
Medical Practice
Type
Molecular Genetic Pathology
Address
Address
660 S Euclid Ave, Saint Louis, MO 63110
Phone
(314) 362-4651
Personal information
See more information about JEFFREY MILBRANDT at radaris.comName
Address
Phone
75 Aberdeen Pl, Saint Louis, MO 63105
Saint Louis, MO
75 Aberdeen Pl, Saint Louis, MO 63105
Professional information
See more information about JEFFREY MILBRANDT at trustoria.com
Professor At Washington University Medical School
Professor At Washington University Medical School
Position:
Professor at Washington University Medical School
Location:
Greater St. Louis Area
Industry:
Biotechnology
Work:
Washington University Medical School
since Oct 1983
-
Professor
Education:
University of Virginia School of Medicine 1980 - 1983
PhD, Biochemistry Washington University in St. Louis School of Medicine 1974 - 1978
MD, Medicine
PhD, Biochemistry Washington University in St. Louis School of Medicine 1974 - 1978
MD, Medicine
Dr. Jeffrey Milbrandt, Saint Louis MO - MD (Doctor of Medicine)
Dr. Jeffrey Milbrandt, Saint Louis MO - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
660 S Euclid Ave SUITE 8232, Saint Louis 63110
(314) 362-4651 (Phone)
Saint Louis Office
660 S Euclid Ave, Saint Louis 63110
(314) 362-5000 (Phone), (314) 454-5396 (Fax)
(314) 362-4651 (Phone)
Saint Louis Office
660 S Euclid Ave, Saint Louis 63110
(314) 362-5000 (Phone), (314) 454-5396 (Fax)
Languages:
English
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1978
Washington Center / School of Medicine
Graduated: 1978
Jeffrey Dean Milbrandt, Saint Louis MO
Jeffrey Dean Milbrandt, Saint Louis MO
Specialties:
Pathology, Anatomic Pathology & Clinical Pathology
Work:
Washington University at St. Louis
660 S Euclid Ave, Saint Louis, MO 63110
660 S Euclid Ave, Saint Louis, MO 63110
Education:
Washington University at St. Louis (1978)
Methods And Compositions For Inhibition Of Axonal Degeneration By Modulation Of The Dlk/Jnk Pathway
Methods And Compositions For Inhibition Of Axonal Degeneration By Modulation Of The Dlk/Jnk Pathway
US Patent:
2010005, Mar 4, 2010
Filed:
Aug 26, 2009
Appl. No.:
12/548411
Inventors:
Aaron DiAntonio - Olivette MO, US
Bradley R. Miller - St. Louis MO, US
Jeffrey D. Milbrandt - Clayton MO, US
Craig A. Press - St. Louis MO, US
Bradley R. Miller - St. Louis MO, US
Jeffrey D. Milbrandt - Clayton MO, US
Craig A. Press - St. Louis MO, US
Assignee:
WASHINGTON UNIVERSITY - St. Louis MO
International Classification:
A61K 31/7088, A61K 31/415, C12Q 1/48
US Classification:
514 44 A, 514406, 435 15
Abstract:
Methods of reducing Wallerian degeneration are disclosed. These methods comprise inhibiting expression or activity of a mixed lineage kinas such as a dual leucine-zipper-bearing kinase (DLK), inhibiting expression or activity of a molecule acting downstream from DLK, such as a c-Jun N-terminal kinase (JNK), or a combination thereof. Further disclosed are methods of screening candidate compounds for DLK inhibition activity. These methods comprise providing a neuronal culture comprising a plurality of axons; contacting the culture with a candidate compound and with an axon degeneration-triggering agent; and comparing axonal degeneration in the culture to a control culture comprising the axon degeneration-triggering agent but not the candidate compound.
Ampk Modulation As A Method Of Regulating Stem Cell And Cancer Stem Cell Proliferation, Self-Renewal And Differentiation
Ampk Modulation As A Method Of Regulating Stem Cell And Cancer Stem Cell Proliferation, Self-Renewal And Differentiation
US Patent:
8133685, Mar 13, 2012
Filed:
Apr 3, 2009
Appl. No.:
12/384446
Inventors:
Jeffrey Milbrandt - Clayton MO, US
Biplab Dasgupta - St. Louis MO, US
Biplab Dasgupta - St. Louis MO, US
Assignee:
Washington University - Saint Louis MO
International Classification:
G01N 33/53, G01N 33/68
US Classification:
435 71
Abstract:
Methods are disclosed for decreasing stem cell proliferation, including cancer stem cell proliferation. These methods comprise administering to stem cells inhibitors of AMP activated protein kinase (AMPK). Methods for promoting stem cell growth by increasing stem cell proliferation, self-renewal and/or differentiation are also disclosed. These methods comprise administering AMPK activators to stem cells. Methods of achieving selective differentiation of stem cells are also disclosed. These methods comprise administering small molecules to stem cells that modulate AMPK activity. Applications of these methods are also disclosed, such as methods of increasing numbers of neuronal progenitor cells. These methods can be used therapeutically, such as for repair of spinal cord injuries, or for stimulating neurogenesis in the hippocampus, and other cell-based therapies. The methods can also be used for screening of compounds that can be activators or inhibitors of AMPK activity.
Methods And Compositions For Inhibition Of Axonal Degeneration By Modulation Of The Dlk/Jnk Pathway
Methods And Compositions For Inhibition Of Axonal Degeneration By Modulation Of The Dlk/Jnk Pathway
US Patent:
2013020, Aug 8, 2013
Filed:
Dec 20, 2012
Appl. No.:
13/722821
Inventors:
WASHINGTON UNIVERSITY - Saint Louis MO, US
Bradley Miller - Saint Louis MO, US
Jeffrey Milbrandt - Saint Louis MO, US
Craig Press - Saint Louis MO, US
Bradley Miller - Saint Louis MO, US
Jeffrey Milbrandt - Saint Louis MO, US
Craig Press - Saint Louis MO, US
Assignee:
WASHINGTON UNIVERSITY - Saint Louis MO
International Classification:
A61K 31/713
US Classification:
514 44 A
Abstract:
Methods of reducing Wallerian degeneration are disclosed. These methods comprise inhibiting expression or activity of a mixed lineage kinase such as a dual leucine-zipper-bearing kinase (DLK), inhibiting expression or activity of a molecule acting downstream from DLK, such as a c-Jun N-terminal kinase (JNK), or a combination thereof. Further disclosed are methods of screening candidate compounds for DLK inhibition activity. These methods comprise providing a neuronal culture comprising a plurality of axons; contacting the culture with a candidate compound and with an axon degeneration-triggering agent; and comparing axonal degeneration in the culture to a control culture comprising the axon degeneration-triggering agent but not the candidate compound.
Methods And Compositions For Treating Neuropathies
Methods And Compositions For Treating Neuropathies
US Patent:
2010004, Feb 25, 2010
Filed:
Jan 28, 2008
Appl. No.:
12/524718
Inventors:
Jeffrey Milbrandt - Clayton MO, US
Biplab Dasgupta - St. Louis MO, US
Biplab Dasgupta - St. Louis MO, US
Assignee:
WASHINGTON UNIVERSITY - St. Louis MO
International Classification:
A61K 49/00, A61K 31/05, C12Q 1/02, A61P 25/00
US Classification:
424 92, 514736, 435 29
Abstract:
Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuinAMPK activity, LKB 1 activity and/or CaMKKβ activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons, alone or in combination with agents that act by other mechanisms. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing such neuropathies.
Methods And Compositions For Treating Neuropathies
Methods And Compositions For Treating Neuropathies
US Patent:
2014001, Jan 9, 2014
Filed:
Jul 26, 2013
Appl. No.:
13/952183
Inventors:
Jeffrey Milbrandt - Clayton MO, US
Biplab Dasgupta - St. Louis MO, US
Biplab Dasgupta - St. Louis MO, US
Assignee:
WASHINGTON UNIVERSITY - St. Louis MO
International Classification:
G01N 33/50, A61K 31/05
US Classification:
514734, 435 29
Abstract:
Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuin AMPK activity, LKB activity and/or CaMKKβ activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons, alone or in combination with agents that act by other mechanisms. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing such neuropathies.